Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
暂无分享，去创建一个
V. Heinemann | M. Lerch | K. Caca | C. Westphalen | J. Siveke | A. Reinacher-Schick | S. Boeck | S. Kanzler | T. Ettrich | F. Kullmann | L. Fischer von Weikersthal | V. Kunzmann | M. Haas | S. Held | M. Fuchs | S. Kruger | M. Schenk | J. Freiberg-Richter